COMPREHENSIVE ASSESSMENT OF THE FUNCTIONAL STATE OF THE KIDNEYS AND HEMODYNAMICS IN THE PROGNOSIS OF CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC PYELONEPHRITIS AND ARTERIAL HYPERTENSION

BACKGROUND. In recent years, there has been an increase in the number of patients with chronic kidney disease (CKD), including due to the prevalence of arterial hypertension (AH). In chronic pyelonephritis, the accelerated development of changes in the cardiovascular system at the background of a decrease in glomerular filtration rate may be due to arterial hypertension (AH). THE AIM: to assess the state of central hemodynamics, indicators of secretory and excretory kidney function, in patients with a combination of secondary chronic pyelonephritis and AH. PATIENTS AND METHODS. 81 patients with secondary chronic pyelonephritis caused by nephrolithiasis in combination with hypertension in the phase of incomplete clinical and laboratory remission were examined. The age of patients is from 25 to 60 years. A comprehensive assessment of the functional state of the kidneys and hemodynamics was carried out, taking into account the data of anamnesis, clinical and paraclinical examination methods. RESULTS. According to the data of dynamic nephroscintigraphy, an elongation of the excretory phase was revealed with the preservation of the secretory phase in both kidneys. A decrease in the estimated glomerular filtration rate was noted already at AG1 degree. According to echocardiography, violations of LV diastolic function were noted with preserved systolic function of the left ventricle. CONCLUSION. We found that in stage 1 CKD, the preservation of secretory function is combined with a slowdown in the excretory function of both kidneys, which may be associated with the processes of sclerosis of the tubulo-interstitial zone of the kidneys at the background of a chronic inflammatory process. The data obtained allow us to express the idea of the expediency of complex cardiorenal dynamic control already in the debut of CKD, which will contribute to improving the effectiveness of nephro- and cardioprotective measures in this cohort of patients.

1. Zhmurov DV, Parfentieva MA, Semenova YV et al. Chronic kidney disease. Colloquium-journal 2020;12 (64) (InRuss.)

2. Kobalava ZD, Villevalde SV, Efremovtseva MA. Chronic kidney disease: definition, slassification, principles of diagnosis and treatment. RKZH 2013; 4(102) (In Russ.)

3. Storozhakov GI, Gendlin GE. The main directions in the treatment of patients with chronic heart failure. Miklosh, M., 2015, 312 p. (In Russ.)

4. Dring B, Hipkiss V. Managing and treating chronic kidney disease. Nurs Times 2015 Feb 11-17;111(7):16-19. PMID: 26477181

5. Mendes A. Chronic kidney disease: supporting at-risk and diagnosed patients. Br J Community Nurs 2015 Feb;20(2):97-98. https://doi.org/10.12968/bjcn.2015.20.2.97. PMID: 25651285

6. Valenza G. Extended-Spectrum-β-Lactamase-Producing Escherichia coli as Intestinal Colonizers in the German Community / G. Valenza, S. Nickel, Y. Pfeifer. Antimicrob Agents Chemother 2014; 58(2):1228-1230

7. Ademola B L, Atanda A T, Aji S A, Abdu A. Clinical, morphologic and histological features of chronic pyelonephritis: An 8-year review. Niger Postgrad Med J 2020 Jan-Mar;27(1):37-41. https://doi.org/10.4103/npmj.npmj_109_19. PMID: 32003360

8. Anna Clementi, Grazia Maria Virzì, Ching Yan Goh, Dinna N. Cruz, Antonio Granata, GirogioVescovo and Claudio Roncob. Cardiorenal syndrome type 4: a review. Cardiorenal Med 2013;3 (1):63-70

9. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol 2020 May;16(5):269-288. https://doi.org/10.1038/s41581-019-0248-y. Epub 2020 Feb 14. PMID: 32060481

10. Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol 2017 Apr 1;312(4):F661-F670. https://doi.org/10.1152/ajprenal.00316.2016. Epub 2017 Jan 25. PMID: 28122713

11. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Massy Z, Wanner C, Anders HJ. Chronic kidney disease. Nat Rev Dis Primers 2017 Nov 23;3:17088. https://doi.org/10.1038/nrdp.2017.88. PMID: 29168475

12. Seccia TM, Caroccia B, Maiolino G, Cesari M, Rossi GP. Arterial Hypertension, Aldosterone, and Atrial Fibrillation. Curr Hypertens Rep 2019 Nov 18;21(12):94. https://doi.org/10.1007/s11906-019-1001-4. PMID: 31741119